Last reviewed · How we verify
Ipilimumab infusion
Ipilimumab blocks CTLA-4 on T cells, removing an inhibitory signal and enhancing anti-tumor immune responses.
Ipilimumab blocks CTLA-4 on T cells, removing an inhibitory signal and enhancing anti-tumor immune responses. Used for Metastatic melanoma, Advanced melanoma.
At a glance
| Generic name | Ipilimumab infusion |
|---|---|
| Also known as | standard treatment |
| Sponsor | The Netherlands Cancer Institute |
| Drug class | CTLA-4 inhibitor |
| Target | CTLA-4 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Ipilimumab is a monoclonal antibody that binds to cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), a negative regulator of T-cell activation. By blocking CTLA-4, the drug removes a 'brake' on the immune system, allowing T cells to become more activated and proliferate, thereby enhancing their ability to recognize and attack cancer cells. This mechanism of immune checkpoint inhibition has demonstrated clinical benefit in melanoma and other malignancies.
Approved indications
- Metastatic melanoma
- Advanced melanoma
Common side effects
- Immune-related colitis
- Immune-related hepatitis
- Immune-related pneumonitis
- Immune-related endocrinopathy
- Fatigue
- Rash
Key clinical trials
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (PHASE2)
- SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (PHASE3)
- Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma (PHASE2)
- A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC) (PHASE2)
- Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors (PHASE1)
- A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC (PHASE3)
- Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer (PHASE1)
- MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ipilimumab infusion CI brief — competitive landscape report
- Ipilimumab infusion updates RSS · CI watch RSS
- The Netherlands Cancer Institute portfolio CI